$4.34
-0.17 (-3.77%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MCRB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 1 expanded access · 5 with posted results
Held by 3 tracked-famous managers (MARSHALL WACE, LLP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC) · FINRA short interest 5.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCTNCT04995653Safety and tolerability of SER-155, including incidence and severity of adverse events, serious adverse events, or adverse events of special interestRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Vancomycin Pre-Treatment, Vancomycin Placebo, SER-155, SER-155 Placebo | Allogeneic Hematopoietic Stem Cell Transplantation | 60 | 2024-07-23actual | 2024-10-01 |
| ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile InfectionNCT03183141results2023-03-31Cohort 1: Recurrence of CDI and Sustained Clinical ResponseOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: SER-109 | Clostridioides Difficile Infection | 263 | 2022-04-29actual | 2023-04-10 |
| A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative ColitisNCT03759041results2022-06-21Clinical Remission (Count of Participants)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Clinical SAP ↗ · Statistical Analysis Plan: Microbiome SAP ↗ | Phase 2 | Terminatedsponsor's stated reason: Due to the lack of a clinical efficacy signal in the induction treatment phase, Seres closed the dosing phases of open label and maintenance portions of the study. Patients who had received prior doses were followed for safety data. | Drug: Vancomycin Pre-Treatment, Placebo for Vancomycin Pre-Treatment, SER-287, Placebo for SER-287 | Ulcerative Colitis | 203 | 2021-05-28actual | 2022-08-12 |
| ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile InfectionNCT03183128results2023-04-27Recurrence of CDI up to 8 WeeksRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: SER-109 · Drug: Placebo | Clostridium Difficile Infection | 182 | 2020-07-03actual | 2023-04-27 |
| SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent RecurrenceNCT02830542Safety and tolerability of SER-262 as assessed by incidence of AEs, lab results, vital signs, ECG, and physical examination findingsRandomized · Quadruple-masked · Prevention | Phase 1 | Completed | Drug: SER-262, Placebo | Clostridium Difficile Infection | 96 | May 2018actual | 2023-02-06 |
| A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative ColitisNCT02618187results2019-06-20Safety and Tolerability of SER-287Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: SERES-101 SAP ↗ · Statistical Analysis Plan: SERES-101 Microbiome SAP ↗ | Phase 1 | Completed | Drug: SER-287, Placebo, Placebo Pre-Treat, Vancomycin Pre-Treat | Ulcerative Colitis | 58 | 2017-12-06actual | 2019-06-20 |
| SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)NCT02437487results2018-07-26Number of Subjects With CDI RecurrenceRandomized · Quadruple-masked · Prevention | Phase 2 | Completed | Drug: SER-109, Placebo | Clostridium Difficile | 89 | Jul 2016actual | 2018-07-26 |
| Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)NCT02437500expanded access | — | Approved for marketing | Biological: SER-109 | Clostridioides Difficile Infection | — | — | 2023-06-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19